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Objective: This study was undertaken to compare the efficacy of
vancomycin prophylaxis with that of cefazolin in preventing surgi-
cal site infections in a tertiary medical center with a high prevalence
of methicillin-resistant staphylococcal infections.
Methods: All adult patients (≥18 years) scheduled for cardiac
surgery requiring sternotomy were randomly assigned to receive
vancomycin (1 g every 12 hours) or cefazolin (1 g every 8 hours).
Prophylaxis was started during the induction of anesthesia and con-
tinued for only 24 hours. Patients were followed up for at least 30
days (1 year for those receiving a cardiac implant). Surgical site
infections were stratified according to the National Nosocomial
Infections Surveillance System risk index.
Results: Of the 885 patients included in the study, 452 received
vancomycin and 433 received cefazolin. The overall surgical site
infection rates were similar in the two groups (43 cases in the vancomycin group,
9.5%, vs 39 cases in the cefazolin group, 9.0%, P = .8). Superficial and deep inci-
sional surgical site infection rates were also similar in the two groups. There was a
trend toward more frequent organ-space infections and infections with β-
lactam–resistant organisms among patients receiving cefazolin, but this trend did
not reach statistical significance. In contrast, surgical site infections caused by
methicillin-susceptible staphylococci were significantly more common in the van-
comycin group (17 cases, 3.7%, vs 6 cases, 1.3%, P = .04). The durations of post-
operative hospitalization and the mortalities were similar in the two groups.
Conclusions: This trial suggests that vancomycin and cefazolin have similar effi-
cacy in preventing surgical site infections in cardiac surgery.
An estimated 468,000 coronary artery bypass grafting (CABG) pro-cedures and more than 60,000 valve implantations are performedannually in the United States.1,2 Surgical site infections (SSIs),particularly organ-space infections, have serious implicationswhen associated with these operations because of the substantialmorbidity, mortality, and expense that they add to the health care
system. The benefits of antibiotic prophylaxis in cardiovascular surgery have been
clearly demonstrated in several placebo-controlled studies,3-6 but the choice of the
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optimal agent remains controversial. Cephalosporins have
been the mainstay of prophylaxis in cardiac surgery because
staphylococci are the most common organisms isolated
from both vein donor sites and chest wound infections.7,8 A
recent review, sponsored by the Infectious Diseases Society
of America and endorsed by both it and the Surgical
Infection Society, recommended, “Vancomycin can be
given instead of cefazolin to patients who are allergic to
cephalosporins or in settings where infections with methi-
cillin-resistant Staphylococcus aureus (MRSA) are preva-
lent.”9 At the time this study was started, only one published
clinical trial had investigated the efficacy of vancomycin
relative to that of cephalosporins in preventing SSIs in car-
diovascular surgery.10 That double-blind control study
showed the superiority of vancomycin to cefazolin in pre-
venting thoracic SSIs other than mediastinitis. This trial was
undertaken to compare the efficacy of cefazolin and van-
comycin in preventing SSIs in cardiovascular surgery at a
large university hospital with a high prevalence of MRSA
infections.
Methods
Patients
The trial was conducted between January 1997 and December
1999 at Rambam Medical Center, Haifa, Israel, where approxi-
mately 400 cardiac operations are performed annually on adult
patients. MRSA infections have been highly prevalent in our insti-
tution for several years.11 A recently published consensus panel’s
definitions for discriminating high rates of MRSA transmission
have suggested a threshold of 0.5 new nosocomial cases of MRSA
per 100 admissions for hospitals with at least 500 beds.12
According to our computerized records, in 1995 and 1996 there
were 3.0 and 2.6 new cases of MRSA infection or colonization,
respectively, per 100 admissions in our cardiac surgery ward, eas-
ily meeting the criterion for high transmission of MRSA.
The study was approved by the local ethical review committee.
Informed consent was not required because we had been using both
drugs for prophylaxis in cardiovascular surgery before the trial. All
adult patients (≥18 years) scheduled for cardiac surgery requiring
sternotomy were considered eligible for the trial. Exclusion criteria
included the presence of active infection, the use of antibiotics
within 2 weeks before the operation, and a previous cardiac opera-
tion requiring sternotomy within 1 year of enrollment in this trial.
Random Assignment and Antibiotic Regimens
Random assignment was performed according to the last digit of
the patient’s national identification number (similar to US social
security number). Patients whose identification number ended in
an even digit were scheduled to receive 1.0 g vancomycin intra-
venously at the induction of the anesthesia over a period of 60
minutes and a similar dose 12 hours later. Patients whose identifi-
cation number ended in an odd digit were scheduled to receive 1 g
cefazolin intravenously over a period of 20 to 30 minutes at the
induction of the anesthesia and two additional similar doses at 8-
hour intervals. Because the timing of administration of prophy-
laxis is of great importance in preventing SSIs,13 we defined the
antibiotic regimen as “preoperative prophylaxis” if the antibiotic
drug was administered in an optimal period of 2 hours or less
before the first surgical incision.
Surgical Preparation and Technical Details
The patients showered with a 7.5% povidone-iodine scrub
(Polydine Cleanser; Fisher Pharmaceutical Laboratories, Tel Aviv,
Israel) the night before the scheduled operation and again on the
morning of the operation. The sites of operation were depilated on
the morning of the operation with a hair-removing cream (Vito;
Heibel Co, Hadera, Israel). In the operating room all operative sites
were scrubbed with the povidone-iodine soap solution and then
painted with a 10% povidone-iodine–ethanol tincture (Polydine
Tincture; Fisher Pharmaceutical Laboratories). The area of ster-
notomy was covered with an iodine membrane (Loban; 3M Health
Care, St Paul, Minn). All operations were done under conventional
cardiopulmonary bypass and moderate hypothermia (rectal temper-
ature 28°C-30°C) with a membrane oxygenator (SpiralGold;
Baxter Healthcare Corporation CardioVascular Group, Irvine,
Calif). Myocardial protection was achieved with short antegrade
and continuous retrograde undiluted blood cardioplegia. The inter-
nal thoracic arteries were used in 96% of the patients undergoing
CABG operations and were harvested either pedicled or skele-
tonized according to the surgeon’s preference with low-grade
diathermy. The greater saphenous vein was harvested through a sin-
gle skin incision by means of standard surgical procedures. All sub-
cutaneous tissues were approximated with continuous absorbable
multifilament sutures (Coated Vicryl; Ethicon, Inc, Somerville,
NJ), and skin wounds were closed with stainless steel clips (Weck
Closure Systems, Research Triangle Park, NC). All operations were
performed by the same team headed by four experienced cardiac
surgeons (Y.B., Z.A., V.K., S.M.).
Patient Evaluation
During hospitalization, patients were evaluated daily by cardiac
surgeons and three times a week by an infection control nurse. At
the discretion of the attending physician, an infectious diseases
specialist was also involved in the evaluation and treatment of
patients. Cultures were obtained as clinically indicated and
processed in the hospital’s microbiology laboratory according to
standard procedures. All patients were followed up for the appear-
ance of postdischarge SSI with at least two visits, the first 1 week
after discharge and the second 3 weeks later. Follow-up was done
in the hospital’s cardiac surgery outpatient clinics with the pres-
ence of an infection control nurse or infectious diseases physician.
Patients receiving a cardiac implant were followed up for at least
1 year. Six patients who did not return to the outpatient clinic were
contacted by telephone by the infection control nurse.
Definitions
Nosocomial SSIs were defined according to the Centers for
Disease Control and Prevention definitions.14 The criteria are
described here.
Superficial SSI. This was an infection involving only skin and
subcutaneous tissue with at least one of the following: purulent
drainage from the incision, positive results of incisional culture,
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and classic inflammatory signs that led to the incision being delib-
erately reopened by the surgeon unless results of an incisional cul-
ture were negative.
Deep incisional SSI. This was an infection involving deep soft
tissues of the incision with at least one of the following: purulent
drainage from the deep incision, a deep incision that sponta-
neously dehisced or was deliberately opened by the surgeon in the
presence of fever (temperature ≥38°C) or localized pain or tender-
ness unless results of an incisional culture were negative, and evi-
dence of infection involving the deep incision found in direct
examination or reoperation.
Mediastinitis. Mediastinitis was reported as a specific organ-
space SSI and was an infection characterized by one of the fol-
lowing: positive results of a culture obtained from mediastinal
tissue or fluid during a surgical operation, a patient fever (temper-
ature ≥38°C), chest pain or sternal instability, mediastinal involve-
ment suggested by a computed tomographic scan, and organisms
cultured from the mediastinal area.
Sternal osteomyelitis. Sternal osteomyelitis was reported as a
specific organ-space SSI and was indicated by a persistent puru-
lent drainage from the sternotomy confirmed by microbiologic
and histopathologic findings.
Pericarditis. Pericarditis was reported as a specific organ-space
SSI and was indicated by organisms cultured from pericardial tissue
or fluid obtained by needle aspiration or during surgical operation.
Endocarditis. Endocarditis was reported as a specific organ-
space SSI and was defined according to the Duke criteria.15
SSI Risk Stratification
SSIs were stratified according to the National Nosocomial
Infections Surveillance System risk index.16 Because all surgical
wounds included in our study were classified as clean, the index
values ranged from 0 to a maximum of 2.
Statistical Analysis
Before the start of this trial, cefazolin had been used for many
years as the routine prophylactic regimen for cardiovascular
surgery in our institution. We estimated the number of patients that
would be required for an adequate examination of the hypothesis
that prophylaxis with vancomycin may result in a significant
reduction in the overall rate of SSIs as follows. Because our rate
of SSIs with cefazolin was not precisely known, we established
this baseline rate by calculating SSI rates occurring during the first
12 months of the study. The overall SSI rate observed among 136
patients receiving cefazolin prophylaxis and included in the study
during this period was 10.5%. A total of 405 operations were
required in each group for the study to have the ability to show a
significant reduction of the SSI rate to 5% with an α level of .20
and β error of .05. The reduction to 5% was chosen as a maximal
figure approximating the median of SSI rate reported by the
TABLE 1. Characteristics of 885 patients receiving cefazolin
or vancomycin for prophylaxis in cardiovascular surgery
Study group
Vancomycin Cefazolin
Subjects (No.) 452 433
Male/female ratio 325:127 311:122
Age (y)
Mean ± SD 60.9 ± 12.2 61.2 ± 12.8
Range 18-85 18-85
60-69 (No.) 347 (76.8%) 323 (75.1%)
>70 (No.) 105 (23.2%) 108 (24.9%)
Type of operation (No.)
CABG (chest and leg) 329 (72.7%) 314 (72.5%)
CABG (chest only) 10 (2.2%) 12 (2.7%)
Cardiac operation other than CABG 81(17.9%) 81 (18.7%)
CABG and other cardiac operation 32 (7%) 26 (6%)
Cardiac implant 90 (19.9%) 70 (16.1%)
American Society of Anesthesiology 413 (91.3%) 390 (90%)
score ≥3 (No.)
Duration of operation (min)
Mean ± SD* 284.8 ± 74 273.7 ± 70.9
Range 110-620 60-780
>5 h (No.) 134 (29.6%) 187 (27%)
Risk index (No.)
Category 0 33 (7.3%) 35 (8.1%)
Category 1 291 (64.3%) 289 (66.7%)
Category 2 128 (28.3%) 109 (25.2%)
Emergency operation (No.) 47 (10.4%) 44 (10.2%)
Stay before operation (d, mean ± SD) 3.8 ± 5.3 4.1 ± 5.1
Preoperative prophylaxis† (No.) 366 (92.4) 369 (94.5)
*P = .02. No other differences were statistically significant at P ≤ .05.
†Definition given in text.
TABLE 2. Outcomes of 885 patients receiving vancomycin or
cefazolin prophylaxis for cardiovascular operations
Vancomycin Cefazolin
(n = 452) (n = 433)
Superficial incisional SSI (No.)
All 25 (5.5%) 20 (4.6%)
Donor site 7 (1.5%) 10 (2.3%)
Chest 18 (4%) 10 (2.3%)
Deep incisional SSI (No.)
All 12 (2.6%) 7 (1.6%)
Donor site 2 (0.4%) 2 (0.4%)
Chest 10 (2.2%) 5 (1.2%)
Organ-space SSI (No.)
All 6 (1.3%) 12 (2.7%)
Mediastinitis 5 (1.1%) 7 (1.6%)
Osteomyelitis 0 3 (0.7%)
Endocarditis 1 (0.2%) 2 (0.4%)
Pericarditis 0 0
Any SSI (No.) 43 (9.5%) 39 (9.0%)
Duration of postoperative 8.7 ± 8 9.3 ± 11
hospitalization (d, mean ± SD)
Deaths (No.) 13 (2.9%) 14 (3.2%)
No differences were significant at P ≤ .05.
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National Nosocomial Infections Surveillance System for CABG
operations (chest and leg) among patients in risk category 2.17 The
significance of the differences between the two groups was deter-
mined by the Student t test or Wilcoxon rank-sum test for contin-
uous variables and by the Fisher exact test or χ2 test for categoric
variables. Calculation was performed with the SPSS statistical
program version 9 (SPSS Inc, Chicago, Ill).
Results
Characteristics of Patients
Between January 1997 and December 1999 a total of 1032
patients were considered eligible and enrolled in the trial.
Of these 144 were excluded, 123 because of deviations
from the antibiotic regimens (110 received both drugs
included in the trial and 13 did not receive the drug indi-
cated by the random assignment) and 21 because of incom-
plete follow-up. Eventually 885 patients completed the
trial; 452 received vancomycin and 433 received cefazolin.
The two groups were similar with respect to patient charac-
teristics, type of surgery, duration of operation, risk index
categories, duration of preoperative hospitalization, and
timing of prophylaxis administration (Table 1).
Outcomes
The outcomes of patients in both groups, including SSIs,
are shown in Table 2. There were 43 SSIs in the van-
comycin group and 39 SSIs in the cefazolin group (overall
SSI rates of 9.5% and 9.0%, respectively, P = .8). The
observed superficial and deep incisional SSI rates in the
vancomycin group were 5.5% and 2.6%, respectively, as
compared with rates of 4.6% and 1.6%, respectively, in the
cefazolin group (P = .6 and P = .4, respectively). Most
organ-space infections in both groups were mediastinitis.
Although organ-space infections were twice as frequent in
the cefazolin group as in the vancomycin group (12 cases,
2.7%, vs. 6 cases, 1.3%), this difference did not reach sta-
tistical significance (P = .1).
The durations of the postoperative hospitalization and
mortalities were similar in the two groups. The overall infec-
tion rates were also similar according to the length of stay in
the hospital before surgery. In the vancomycin group there
were 35 SSIs among 385 patients hospitalized for 6 days or
less before the operation and 8 SSIs among 67 patients with
preoperative stays of 7 days or longer (9% vs 11.9%, P = .6).
In comparison, in the cefazolin group there were 30 SSIs
among 357 patients with stays of 6 days or less before the
operation and 9 SSIs among 76 patients with preoperative
stays of 7 days or longer (8.4% vs 11.8%, P = .4).
Table 3 summarizes the distribution of pathogens iso-
lated in both groups of patients according to the different
types and sites of SSI. Pathogens isolated from SSIs were
similarly distributed in both groups, although some differ-
ences were found that did not reach statistical significance.
More than 60% of SSIs were due to gram-positive cocci. S
aureus was the leading pathogen, closely followed by coag-
ulase-negative staphylococci. Gram-negative bacilli caused
approximately 50% of SSIs. Nevertheless, there was a trend
toward more common infections with β-lactam–resistant
TABLE 3. Microorganisms isolated according to surgical site infections and antibiotic prophylaxis*†
Vancomycin Cefazolin
Leg (n = 9) Chest (n = 34) Leg (n = 12) Chest (n = 27)
Superficial Superficial Superficial Superficial
and deep and deep and deep and deep
incisional incisional Organ-space incisional incisional Organ-space
Pathogens (n = 9) (n = 28) (n = 6) Total (n = 43) (n = 12) (n = 15) (n = 12) Total (n = 39)
Coagulase-negative staphylococci
All 3 (6.9%) 9 (20.9%) 1 (2.3%) 13 (30.2%) 1 (2.5%) 4 (10.2%) 4 (10.2%) 9 (23%)
Methicillin-resistant 1 (2.3%) 5 (11.6%) 6 (14%) 4 (10.2%) 4 (10.2%) 8 (20.5%)
Methicillin-susceptible 2 (4.6%) 4 (9.3%) 1 (2.3%) 7 (16.2%) 1 (2.5%) 1 (2.5%)
S aureus
All 3 (6.9%) 4 (9.3%) 5 (11.6%) 12 (27.9%) 4 (10.2%) 4 (10.2%) 4 (10.2%) 12 (30.7%)
Methicillin-resistant 2 (4.6%) 2 (4.6%) 1 (2.5%) 2 (5.1%) 4 (10.2%) 7 (17.9%)
Methicillin-susceptible 3 (6.9%) 4 (9.3%) 3 (6.9%) 10 (23.2%) 3 (7.6%) 2 (5.1%) 5 (12.8%)
Enterococci 1 (2.3%) 1 (2.3%) 1 (2.5%) 3 (7.6%) 1 (2.5%) 5 (12.8%)
Gram-negative bacilli 3 (6.9%) 18 (41.8%) 21 (48.8%) 6 (15.3%) 8 (20.4%) 6 (15.3%) 20 (51.2%)
Nocardia 1 (2.3%) 1 (2.3%)
Culture negative 2 (4.6%) 1 (2.3%) 3 (6.9%) 3 (7.6%) 1 (2.5%) 4 (10.2%)
*None of these differences is significant at P < .05.
†Some infections were polymicrobial.
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gram-positive cocci (eg, MRSA and methicillin-resistant
enterococci) in the cefazolin group (18 of 433 patients,
4.2%, vs 9 of 452 patients, 2%, P = .09). In contrast, SSIs
due to methicillin-susceptible S aureus and coagulase-neg-
ative staphylococci were significantly more frequent among
patients who received vancomycin prophylaxis (17 of 452
patients, 3.7%, vs 6 of 433 patients, 1.3%, P = .04). The
mean preoperative stays among patients with SSIs caused
by methicillin-susceptible staphylococci and by MRSA
were similar (4.65 ± 5.0 days vs 5.7 ± 10.5 days, P = .7).
Polymicrobial infection rates were also similar in the two
groups; 8 of 43 infections (18.6%) in the vancomycin group
were polymicrobial, as compared with 11 of 39 infections
(28.2%) in the cefazolin group (P = .4).
Of the 38 cases of bloodstream infection (BSI) that
occurred during the study, 20 (4.4%) were observed in the
vancomycin group and 18 (4.1%) were seen in the cefazolin
group (P = .9). In both groups BSIs were significantly more
common among patients with SSIs than among those with-
out SSIs. In the vancomycin group 9 BSIs occurred among
43 patients with SSIs (20.9%), as compared with 11 BSIs
observed in 409 patients (2.6%) without SSIs (P < .001). In
the cefazolin group there were 9 BSIs among 39 patients
with SSIs (23%), as compared with 9 BSIs among 394
patients (2.2%) without SSIs (P < .001). BSIs occurred only
among patients with chest infections. Pathogens isolated in
cases of BSI are shown in Table 4.
Discussion
Worldwide the cephalosporin antibiotics, in particular the
first- and second-generation agents, are the most widely
used drugs in surgical practice, including in cardiac
surgery.18,19 Despite a relatively large number of studies, no
cephalosporin drug has emerged as clearly superior to the
others in reducing SSI rates. A meta-analysis of antibiotic
prophylaxis that included six studies of cefazolin versus
cefamandole or cefuroxime20 concluded that the second-
generation cephalosporins were associated with lower
prevalence of wound infection than seen with cefazolin.
However, subsequent randomized double-blind trials failed
to show the superiority of cefamandole or cefuroxime over
first-generation cephalosporins in cardiac surgery.10,21 The
use of vancomycin for prophylaxis in cardiac surgery,
although much more controversial, might be justified in the
light of many observations. First, organ-space infections,
although infrequent, have devastating consequences.
Second, coagulase-negative staphylococci and S aureus, the
most important pathogens responsible for SSIs in cardiac
surgery, are frequently resistant to β-lactam antibiotics.
Third, some studies have shown that more than 80% of sur-
gical patients who receive a first-generation cephalosporin
for prophylaxis become colonized with methicillin-resistant
coagulase-negative staphylococci by the seventh postopera-
tive day.22,23 Finally, the superiority of vancomycin over
cephalosporins in cardiac surgery has been suggested in two
previous studies. Maki and colleagues10 showed in a
prospective, double-blind trial that vancomycin, relative to
cefazolin and cefuroxime, was associated with a statisti-
cally significant reduction in the rate of thoracic surgical
SSIs other than mediastinitis. In addition, the mean duration
of postoperative hospitalization in the vancomycin group
was significantly reduced relative to that observed in the
cefazolin group. In a preliminary report, Nafziger and col-
leagues24 showed that prophylaxis with a first-generation
cephalosporin instead of vancomycin appeared to be a risk
factor for mediastinitis.
On the other hand, two major problems with the prophy-
lactic use of vancomycin in surgery should be seriously con-
sidered. First, several studies have concluded that the use of
vancomycin prophylaxis in cardiac and noncardiac surgery
may result in serious untoward effects, particularly hypoten-
sion.25,26 Second, and more important, are the alarming prob-
lems of vancomycin-resistant enterococci27 and more recently
glycopeptide-intermediate–resistant S aureus.28 Reports of
these emerging resistances have significantly altered attitudes
toward the use of vancomycin prophylaxis in surgery. As a
consequence, recent guidelines for prevention of SSIs
strongly recommend avoiding the routine use of vancomycin
TABLE 4. Pathogens isolated from BSIs among 38 patients
receiving vancomycin or cefazolin prophylaxis in cardio-
vascular surgery
Vancomycin Cefazolin
(n = 20) (n = 18)
No. % No. %
Gram-positive cocci
All 12 60 10 55.5
Methicillin-susceptible S aureus 6 30 2 11.1
Methicillin-resistant S aureus 2 10 4 22.2
Methicillin-susceptible coagulase- 1 5 0 0
negative staphylococci
Methicillin-resistant coagulase- 2 10 2 11.1
negative staphylococci
Enterococci 1 5 2 11.1
Gram-negative bacilli
All 11 55 7 38.8
Klebsiella species 6 30 3 16.6
Enterobacter species 2 10 0 0
Serratia species 2 10 1 5.5
Others 1 5 3 16.6
Fungi
C albicans 0 2 11.1
No differences were significant at P < .05. Some infections were polymi-
crobial.
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for antimicrobial prophylaxis in surgery.29 These recommen-
dations may be strengthened by a recently published trial30
that showed similar results when vancomycin and cefuroxime
were used for antimicrobial prophylaxis in CABG.
The major objective of our trial was to investigate
whether SSI rates associated with cardiac surgery could be
reduced by the use of vancomycin prophylaxis in an insti-
tution with a high prevalence of MRSA infections.
Although we observed a trend toward more serious infec-
tions occurring among patients who received cefazolin pro-
phylaxis, this trend did not reach statistical significance. As
could be expected, SSIs caused by methicillin-resistant
gram-positive cocci were more common among patients
who received cefazolin prophylaxis. However, the overall
results were counterbalanced by the fact that infections with
methicillin-susceptible staphylococci were significantly
more frequent in the vancomycin group. Paradoxically,
infections with gram-negative bacilli were equally common
in the two groups.
Although a prolonged preoperative stay is a likely surro-
gate for severity of illness, it is frequently suggested as a
patient characteristic associated with increased SSI risk.29
Moreover, infections with resistant organisms, including
MRSA, are typically hospital acquired. Therefore one could
make a point in favor of the use of vancomycin as surgical
prophylaxis for patients with a prolonged preoperative stay.
In this study, however, SSI rates and infections with MRSA
were not affected by a more prolonged preoperative stay.
Thus our results do not support the use of vancomycin pro-
phylaxis in this setting.
It appears that the random assignment achieved a good
balance among the various covariates of the two groups
(Table 1). Nevertheless, the fact that the trial could not be
performed in a double-blinded fashion represents an impor-
tant limitation of this study. Taking this limitation in con-
sideration, we conclude that this study could not show any
clear advantage of vancomycin over cefazolin in reducing
SSI rates in cardiac surgery at our institution, where the
prevalence of MRSA infections is high. Possible explana-
tions may include the superiority of cefazolin over van-
comycin in preventing infections with β-lactam–susceptible
organisms or the possibility that some serious infections
complicating cardiac operations are initiated after the oper-
ation in a critical care setting, rather than being acquired
during operation.31,32 Our data appear to support the con-
tinuing efforts to restrict the prophylactic use of van-
comycin in surgical practice.
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